Workflow
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
IKTInhibikase Therapeutics(IKT) GlobeNewswire News Room·2024-10-09 13:18

-- Aggregate investment of up to approximately 275Millionbyhealthcare−focusedinvestmentfunds,ledbySoleusCapital−−BOSTONandATLANTA,Oct.09,2024(GLOBENEWSWIRE)−−InhibikaseTherapeutics,Inc.(Nasdaq:IKT)("Inhibikase"orthe"Company"),aclinical−stagepharmaceuticalcompanydevelopingproteinkinaseinhibitortherapeuticstomodifythecourseofcardiopulmonaryandneurodegenerativediseasethroughAbelsonTyrosineKinaseinhibition,todayannouncedthepricingofanapproximately275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approximately 110 ...